MARKET

STSA

Satsuma Pharmaceuticals, Inc.
STSA
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-1.8261
-
0.9687
36,467,747.80
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 06/09/2023 11:30
Satsuma migraine therapy accepted for FDA review
Seeking Alpha · 05/18/2023 20:34
Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(b)(2) NDA For STS101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Benzinga · 05/18/2023 20:03
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review
MT Newswires · 05/18/2023 17:25
Satsuma Pharmaceuticals, Inc.: Current report
Press release · 05/18/2023 16:30
JonesTrading Sticks to Its Hold Rating for Satsuma Pharmaceuticals (STSA)
TipRanks · 05/15/2023 12:05
BRIEF-Shin Nippon Biomedical Laboratories Ltd - Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Reuters · 05/07/2023 23:37
BRIEF-Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
Reuters · 05/03/2023 21:20
More

Webull offers Satsuma Pharmaceuticals, Inc. stock information, including NASDAQ: STSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STSA stock methods without spending real money on the virtual paper trading platform.